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Objectives
Stratified medicine has been defined as using a biomarker
to match a patient to a cohort that has exhibited a differen-
tial response to a treatment. This is important where the
proportion of patients benefiting from treatment is low and
possible adverse events can be serious. To maximise patient
benefit, valid predictive biomarkers need to be used. Several
trial designs have been proposed to evaluate the use of pre-
dictive biomarkers in clinical practice including: enrich-
ment, stratified and biomarker-based strategy design.
Our aim was to review the EMA indications that
include a predictive biomarker in order to investigate
the type and strength of evidence considered sufficient
for such decisions.
Methods
We have undertaken a review to identify predictive bio-
markers included in EMA indications, together with the
supporting study designs and strength of evidence. The
authorised, refused, withdrawn and pending decisions
on the EMA website were reviewed in October 2010.
Where predictive biomarkers were identified, data was
collected on the details of the therapeutic indication and
supporting evidence.
Results
Fifteen predictive biomarkers were included in the indi-
cations of 18 drugs. For one biomarker the license was
refused and for one withdrawn. Only three biomarkers
were included in an indication before 2004. Five of the
18 drugs had an orphan designation.
Thirteen biomarkers for 10 drugs were included in indi-
cations for treatment of various cancers (including a range
of haematological diseases, breast, colorectal, gastric and
lung cancer). Two biomarkers were included in the indica-
tions of four drugs for the treatment of HIV infections.
The majority of identified studies were enrichment
design or used a subgroup analysis (sometimes post hoc)
to evaluate the predictive biomarker. One stratified and
one marker- based strategy design study was identified.
Conclusions
The specialties where predictive biomarkers were identi-
fied were limited to cancer and HIV infection. No predic-
tive biomarkers have been identified in other specialties
where treatments are often effective only in a relatively
small subgroup of patients (such as mental health).
Our review found that evidence from subgroup ana-
lyses and studies with an enrichment design has been
often considered sufficient to grant marketing authorisa-
tion. Such results would ordinarily be interpreted with
caution due to underlying methodological limitations.
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